EP1673075A2 - Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases - Google Patents
Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseasesInfo
- Publication number
- EP1673075A2 EP1673075A2 EP04790485A EP04790485A EP1673075A2 EP 1673075 A2 EP1673075 A2 EP 1673075A2 EP 04790485 A EP04790485 A EP 04790485A EP 04790485 A EP04790485 A EP 04790485A EP 1673075 A2 EP1673075 A2 EP 1673075A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- unsubstituted
- compounds
- substituted
- tautomers
- stereoisomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C325/00—Thioaldehydes; Thioketones; Thioquinones; Oxides thereof
- C07C325/02—Thioketones; Oxides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
- C07F9/5333—Arylalkane phosphine oxides or thioxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- New alanyl aminopeptidase inhibitors for the functional influencing of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
- the ubiquitous alanyl aminopeptidases include the aminopeptidase N (APN, CD 13, EC 3.4.11.2), which predominantly occurs as type II membrane protein, and the cytosolic, soluble alanyl aminopeptidase (EC 3.4.11.14, puromycin-sensitive aminopeptidase, aminopeptidase PS, Enkephaiin-degrading aminopeptidase). Both peptidases are metal-dependent and catalyze the hydrolysis of peptide bonds behind N-terminal amino acids of oligopeptides, in the case of APN with a preference for alanine at the N-terminus (AJ Barrett et al .: Handbook of Proteolytic Enzymes, Academic Press 1998 ).
- the receptor for coronaviruses which among other things cause the disease SARS, is the aminopeptidase N.
- the isolated inhibition of the alanyl aminopeptidases and analog peptidases leads to a strong inhibition of D ⁇ A synthesis on immune cells and thus to cell proliferation and to a change in cytokine production, in particular to induction of the immunoregulatory effect TGF-ßl (international patent application WO 01/89569 AI, international patent application WO 02/053170 A3).
- Alanyl aminopeptidase inhibitors cause a strong induction of TGF- ⁇ 1 (international patent application PCT EP 03 07199) on regulatory T cells.
- a reduction or delay in acute and chronic cerebral damage processes has been demonstrated in the neuronal system by inhibiting the alanyl aminopeptidases, but especially by combined inhibition of the alanyl aminopeptidases and the dipeptidyl peptidase IV and analogous enzymes (international patent application WO 02/053169 A3 and German patent application DE -A 103 37 074.9). It has also been shown on fibroblasts (German patent application DE-A D 103 30 842.3), keratinocytes (international patent application WO 02/0531 70) and sebocytes (international patent application PCT EP 03/02356) that the inhibition of alanyl aminopeptidases, but especially that Inhibition of both peptidase systems, an inhibition of growth and a change in cytokine production.
- the object of the present invention was to find further effective inhibitors of alanyl aminopeptidases.
- low molecular weight, easily accessible compounds should be found which are effective, i.e. H. allow effective inhibition of alanyl aminopeptidases and analog enzymes.
- the invention therefore relates to substances which specifically inhibit Ala-p-nitroanilide-cleaving peptidases.
- the present invention relates to compounds of the general formulas AI to A14 according to claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27 as well as tautomers and stereoisomers of the compounds mentioned general formulas AI to A14 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for use in medicine.
- the invention relates to specific, preferred compounds of the special formulas AI.001 to A14.003, which fall under the above general formulas AI to A14 and which are exemplary, but not restrictive, in claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28 are listed in the form of tables, and tautomers and stereoisomers of the compounds mentioned of the general formulas AI .001 to AI 4.003 and pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof, for use in medicine.
- the invention further relates to pharmaceutical compositions which comprise at least one compound of one of the general formulas AI to A14, optionally in combination with carriers or adjuvants which are customary per se.
- the invention further relates to cosmetic compositions which comprise at least one compound of one of the general formulas AI to AI 4, optionally in combination with conventional carriers or adjuvants.
- the invention further relates to the use of at least one compound of the general formulas AI to A14 or at least one of the abovementioned pharmaceutical or cosmetic compositions for inhibiting the activity of alanyl aminopeptidases or analogous enzymes, either alone or in combination with inhibitors of DPIV or analogous enzymes ,
- the invention further relates to the use of at least one compound of the general formulas AI to A14 or at least one of the abovementioned pharmaceutical or cosmetic compositions for topically influencing the activity of alanyl aminopeptidases or analogous enzymes, either alone or in combination with inhibitors of DPIN or analogues enzymes.
- the invention further relates to the use of at least one compound of the general formulas AI to A14 or at least one of the aforementioned pharmaceutical or, if appropriate, also cosmetic compositions for the prophylaxis and therapy of a whole number of diseases, which are claimed in claims 33 to 45 by way of example.
- the compounds of the general formulas AI to AI 4 in particular those in Table 1 to 14 listed, particularly preferred individual compounds AI.001 to A14.003, as such or as starting materials for other substances and in combination with inhibitors of DPIN and analogous enzymes for the therapy of diseases with an excessive immune response (autoimmune diseases, allergies and transplant rejections), of other chronic inflammatory ones Diseases, neuronal diseases and cerebral damage, skin diseases (including acne and psoriasis), tumor diseases and special viral infections (including SARS) can be used.
- the invention further relates to the use of at least one compound of the general formulas AI to A14 or at least one of the aforementioned pharmaceutical or cosmetic compositions for the manufacture of a medicament for inhibiting the activity of alanyl aminopeptidases or analogous enzymes, either alone or in combination with inhibitors of DPIN or analog enzymes.
- the invention further relates to the use of at least one compound of the general formulas AI to A14 or at least one of the aforementioned pharmaceutical or cosmetic compositions for the manufacture of a medicament for topically influencing the activity of alanyl aminopeptidases or analogous enzymes, either alone or in combination with inhibitors the DP1Y or analog enzymes.
- the invention further relates to the use of at least one compound of the general formulas AI to AI 4 or at least one of the aforementioned pharmaceutical or optionally also cosmetic compositions for the production of a medicament for the prophylaxis and therapy of a whole number of diseases, which are exemplary in claims 48 to 60 are claimed.
- the compounds of the general formulas AI to AI 4 in particular the particularly preferred individual compounds AI.001 to A14.003 listed in Tables 1 to 14, as such or as starting materials for further substances and in Combination with DPIV inhibitors and analogous enzymes for the manufacture of a medicament for the therapy of diseases with excessive immune response (autoimmune diseases, allergies and graft rejections), other chronic inflammatory ones Diseases, neuronal diseases and cerebral damage, skin diseases (including acne and psoriasis), tumor diseases and special viral infections (including SARS) can be used.
- the invention further relates to a method for inhibiting the activity of the alanyl peptidases or analogous enzymes alone or in combination with inhibitors of the DPIV and analogous enzymes by administration of at least one compound of the general formulas AI to A14 or at least one of the above pharmaceutical or cosmetic compositions in one for the Inhibition of the amount of enzyme activity required.
- the invention further relates to a method for topically influencing the activity of alanyl peptidases or analogous enzymes alone or in combination with inhibitors of DPIV and analogous enzymes by administration of at least one compound of the general formulas AI to AI 4 or at least one of the above pharmaceutical or cosmetic compositions in one amount required to inhibit enzyme activity.
- the invention further relates to a method for the prophylaxis and / or therapy of one of the diseases or conditions claimed in claims 63 to 76 while inhibiting the activity of alanyl peptidases or analogous enzymes alone or in combination with inhibitors of DPIN and analogous enzymes by administration of at least one compound of the general formulas AI to AI 4 or at least one of the above pharmaceutical or cosmetic compositions in an amount required for prophylaxis or therapy.
- analogous enzymes refers to enzymes which have an enzyme activity analogous to the membrane-bound alanyl aminopeptidase, as is the case, for example, for the cytosolic alanyl aminopeptidase.
- the term is in this sense also explained in the above-cited publication "AJ Barrett et al .: Handbook of Proteolytic Enzymes, Academic Press 1998".
- radicals Rn are in the general formulas AI to A14, as can be seen from claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27 in general form , ie the radicals Rl, R2, R3, R4, R5, R6, R7, R8, R9, R10, Rl l, R12 and R13 each independently for a radical which is selected from the group consisting of hydrogen , un- substituted or substituted, straight or branched C ⁇ - to C 12 - alkyl, C 2 - to C 12 alkenyl and C 2 - to C 12 alkynyl, hydroxy, thiol, C ⁇ - C 12 alkoxy, - to C 12 - alkylthio, unsubstituted or substituted, uncondensed or condensed, optionally containing one or more heteroatoms from the group consisting of N, O, P and S aryl and cycloalkyl, unsubstituted or substituted amino, unsubstituted or
- radicals Rn in embodiments according to the invention if they represent unsubstituted straight-chain or branched alkyl groups having 1 to 12 carbon atoms, in preferred embodiments methyl, ethyl, n-propyl, i-propyl, n-butyl, i - Butyl, sec-butyl, tert-butyl, n-pentyl, i-pentyl, sec-pentyl, tert-pentyl, n-hexyl, i-hexyl, 3-methylpentyl, 2-ethylbutyl, 2,2-dimethylbutyl and for the residues heptyl, octyl, nonyl.
- Decyl, undecyl and dodecyl all straight-chain and branched isomers.
- particularly preferred from the aforementioned group are alkyl groups with 1 to 6 carbon atoms; of these, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and tert-butyl are more preferred.
- the radicals Rn can also stand for straight-chain and branched alkenyl groups with several double bonds.
- Preferred radicals from this group are the butadienyl group and the isoprenyl group.
- Particular preferred from the aforementioned group are alkenyl Groups with 2 to 6 carbon atoms; of these, vinyl, allyl, 1-butenyl and 2-butenyl are more preferred.
- the radicals Rn when they represent unsubstituted straight-chain or branched alkynyl groups having 2 to 12 carbon atoms, in preferred embodiments are ethynyl, propynyl, 1-butynyl, 2-butynyl, and for the radicals pentynyl, hexynyl, Heptinyl, octynyl, nonynyl, decynyl, undecynyl and dodecynyl all straight-chain and branched residues conceivable with regard to the position of the C ⁇ C triple bond.
- particularly preferred from the aforementioned group are alkynyl groups with 2 to 6 C atoms; of these, ethynyl, propynyl, 1-butynyl and 2-butynyl are more preferred.
- both straight-chain and branched alkyl, alkenyl or alkynyl radicals can be substituted in a further embodiment.
- the substituents can be located at any position on the basic structure formed from carbon atoms and can be selected from the group consisting of halogen atoms such as fluorine, Cng, bromine and iodine, alkyl groups with 1 to 6 C atoms, alkoxy groups with 1 to 6 C atoms in the alkyl radical and unsubstituted or with one or two alkyl radicals each independently substituted by 1 to 6 carbon atoms.
- the radicals Rn in the general formulas AI to A14 Ci- to C 12 alkoxy mean radicals or C to C 12 - alkylthio radicals.
- the abovementioned definitions of straight-chain and branched alkyl radicals also apply to the C 1 -C 12 -alkyl groups of these alkoxy or alkylthio radicals.
- Straight-chain Ci- are particularly preferred to C 6 alkoxy radicals and straight-chain Ci to C6 alkylthio radicals, and are particularly preferably the radicals methoxy, Etlioxy, n-propoxy, methylthio, ethylthio and n-propylthio.
- the radicals Rn of the general formulas AI to AI 4 can also represent unsubstituted or substituted cycloalkyl radicals. According to the invention, these can preferably contain three to eight atoms in the ring and can either consist of finally consist of carbon atoms or contain one or more heteroatoms.
- cyclopentyl particularly preferred among the purely carbocyclic rings are cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptenyl, cycloheptadienyl and cycloheptatrienyl;
- cycloalkyl radicals containing heteroatoms in further embodiments of the invention are the radicals tetrahydrofuranyl, pyrrolidinyl, pyrazolidinyl, hnidazolidinyl, piperidinyl, piperazinyl and morpholinyl.
- Possible substituents on these carbocyclic or heterocyclic cycloalkyl radicals can be selected from the above group of substituents for linear alkyl groups.
- the radicals Rn on the compounds of the general formulas AI to A14 can be uncondensed or condensed aryl radicals optionally containing one or more heteroatoms from the group consisting of N, O, P and S.
- the aryl radicals can consist of one or more rings, preferably two rings in the case of several rings; a ring can further preferably have five, six or seven ring members.
- benzo-condensed rings are particularly preferred, i. H. Ring systems in which at least one of the rings is an aromatic six-membered ring.
- the aryl radicals consisting purely of carbon atoms are particularly preferably selected from phenyl, cyclopentadienyl, cycloheptatrienyl and naphthyl;
- Aryl radicals containing particularly preferred heteroatoms are selected, for example, from indolyl, coumaronyl, thionaphthenyl, quinolinyl (benzopyridyl), quinazolinyl (benzopyrimidinyl) and quinoxylinyl (benzopyrazinyi).
- aryl radicals consisting of one ring as well as several rings, both containing only carbon atoms and also containing heteroatoms, can be substituted according to the invention.
- the substituents can be located at any position in the ring system, both on the carbon atoms and on the heteroatoms, and can be selected, for example, from the group consisting of halogen atoms such as fluorine, chlorine, bromine and iodine, alkyl groups with 1 to 6 carbon atoms, Alkoxy groups with 1 to 6 carbon atoms in the alkyl radical and unsubstituted or with one or two alkyl radicals each with independently substituted 1 to 6 C atoms amino groups.
- the substituents Rl and Rm therein have the meanings defined in detail above for the radicals Rn and can be identical or different.
- substituents Rm of substituted carbonyl radicals or substituted thiocarbonyl radicals have the meanings defined above in detail for the possible substituents of the radicals Rn.
- the radicals Rn are connected to the respective basic structures of the general formulas AI to A14 via the hetero atom or one of their heteroatoms.
- the radicals Y each independently represent one of the radicals O, S or NRn, for example NR3 or NR4 or NR5, which are bonded to a carbon atom via a double bond
- the radicals Rn (for example R3 or R4 or R5) may have the meanings given above, including the meaning water material.
- Y particularly preferably represents O bonded to a C atom via a double bond.
- X, XI, X2 and Z represent radicals which each have a CX single bond (or C-Xl single bond or C-X2 single bond) or a CZ single bond are bonded to two different carbon atoms.
- radicals X and Z in the general formulas in which they occur each independently represent one of the radicals>NH,> NRn (e.g.> NR5 or> NR10), each bonded to a single bond to two different carbon atoms, - O-, -S-, -CH 2 -, -CHRn- or -CRn 2 -, in which the radicals Rn have the meaning given above, or stand for one of the radicals bonded via three single bonds to three different carbon atoms, > CH- or> CRn- (e.g.> CR8- or> CR9-), wherein Rn (e.g. R8, R9) have the meanings given above.
- NRn e.g.> NR5 or> NR10
- Z represents P or S.
- X and Z independently of one another represent radicals from the group consisting of hydroxy, thiol, - to C 12 -alkoxy, C ⁇ - to C 12 -alkylthio, unsubstituted or substituted, uncondensed or condensed, optionally one or more heteroatoms from the group consisting of N, O, P and S containing aryl and cycloalkyl and amino (NH 2 , NHRl, NR1R2), in which all of the aforementioned meanings of X and Z correspond to those for alkoxy, alkylthio, aryl, cycloalkyl and amino , which were defined above for the radicals Rn of the general formulas AI to AI 4 in detail.
- XI and X2 can be identical or different and are selected independently of one another from the group consisting of hydroxyl, thiol, Ci to -C 2 alkoxy, - to C 12 alkylthio, unsubstituted or substituted, uncondensed or condensed, optionally containing one or more heteroatom (s) from the group N, O, P and S aryl or cycloalkyl, hydroxy, thiol, and amino (NH 2 , HNR1, NR1R2).
- Rl and R2 have the meanings given above.
- the radicals R8, R9 and RIO have the meanings given above.
- the compounds corresponding to the general formulas AI to A14 in general and the special compounds AI .001 to AI 4.003 mentioned in Tables 1 to 14 are claimed in preferred embodiments of the invention for use in medicine.
- the term “for use in medicine” is understood here in its broadest meaning as in the patent claims and relates to all conceivable fields of application in which the compounds of the general formulas AI to 14 defined by the present invention and, in preferred embodiments, the compounds AI .001 to A14.003, as specifically listed in Tables 1 to 14, can be effective in connection with medically relevant conditions of the mammalian body, in particular the human body.
- the compounds of the general formulas AI to AI 4 are used in general and the preferred compounds AI.001 to A14.003 according to Tables 1 to 14 are used either in the form of the use of a single compound or in the form of the Use of several compounds of the general formulas AI to A14 (in particular the preferred compounds AI.001 to A14.003 according to Tables 1 to 14) instead.
- the use of one or more of the compounds of the general formulas AI to AI 4, preferably one or more compounds from the group selected from the compounds AI.001 to A14.003 according to Tables 1 to 14 Combination with other active ingredients, for example with one or more compounds, the effectiveness in the indi- bition of alanyl aminopeptidases or of analogous enzymes (i.e. enzymes with the same substrate specificity) and / or effectiveness in the inhibition of other enzymes, for example the dipeptidyl peptidase IN (DPIV) or of analogous enzymes (i.e. enzymes with the same substrate specificity).
- DPIV dipeptidyl peptidase IN
- analogous enzymes i.e. enzymes with the same substrate specificity
- inhibitors which act as inhibitors of alanylamino peptidase may include, for example: actinonine, leuhistine, phebestine, amastatin, admire, probestin, ⁇ -aminothiols, ⁇ -aminophosphinic acids, aminophosphinic acid derivatives, preferably D-Phe- ⁇ / '- PO (OH) -CH 2 ] -Phe Phe.
- Particularly preferred known inhibitors for the alanyl amino peptidase to be used together with the compounds according to the invention are Bestaun (Ubenimex), Actinonin, Probestin, Phebestin, RB3014 or Leuhistin.
- a further embodiment of the invention relates to pharmaceutical preparations which contain at least one, optionally also two or even more, compound (s) of the general formulas AI to A14, particularly preferably selected from the compounds AI .001 to A14.003 according to Tables 1 to 14 , include.
- Such pharmaceutical preparations comprise one or more of the compounds mentioned in each case in such an amount as is necessary for the development of a pharmaceutical effect.
- the person skilled in the art can determine such quantities easily and without inventive step using a few routine tests; they are generally in the range from 0.01 to 1000 mg of each of the compounds of the general formulas AI to A14, particularly preferably the compounds AI.001 to A14.003 according to Tables 1 to 14, per administration unit, even more preferably in the range from 0 , 1 to 100 mg of each of the compounds mentioned per dosage unit.
- Quantities tailored to the individual mammalian organism or human organism can easily determine and, if necessary, also provide that a sufficient concentration of the compounds (s) to be used is achieved by administering divided or several dosage forms.
- a further embodiment of the invention relates to cosmetic preparations which contain at least one, optionally also two or even more, compound (s) of the general formulas AI to A14, particularly preferably selected from the compounds AI .001 to A14.003 according to Tables 1 to 14 , include.
- Such cosmetic preparations comprise one or more of the compounds mentioned in each case in such an amount as is necessary for the development of a desired, for example cosmetic, effect.
- the person skilled in the art can determine such quantities easily and without inventive step using a few routine tests; they are generally in the range from 0.01 to 1000 mg of each of the compounds of the general formulas AI to A14, particularly preferably the compounds AI.001 to A14.003 according to Tables 1 to 14, per administration unit, even more preferably in the range from 0 , 1 to 100 mg of each of the compounds mentioned per dosage unit.
- the person skilled in the art can easily determine quantities which are matched to the respective individual mammal organism or human organism and, if appropriate, also provide that a sufficient concentration of the compounds to be used is achieved by administering divided or several dosage forms.
- the one or more compounds according to the present invention or pharmaceutical or cosmetic preparations containing them are administered simultaneously with known carriers and / or auxiliaries (adjuvants).
- carriers and auxiliary substances are known to the person skilled in the art as such and also with regard to their function and mode of use and therefore do not require any detailed explanation at this point.
- the invention also includes pharmaceutical preparations which comprise: one or more of the inhibitors of DP IN or the inhibitors of enzymes with DP IV-analogous enzyme activity or / and the inhibitors of APN or the inhibitors of enzymes with APN-analogous enzyme activity according to the prior art, together with one or more compound (s) of the general formulas AI to AI 4, particularly preferred together with one or more of the Neritatien, which are selected from Neritatien AI .001 to A14.003 from Table 1 to 14, in spatially restricted formulation in combination with known carrier, auxiliary and / or additives for simultaneous or immediately consecutive ner administration with the aim of a common effect.
- the Ner administration of the Neritatien of the general formulas AI to A14 in general and preferably of the compounds AI.001 to A14.003 according to Tables 1 to 14 or pharmaceutical or cosmetic preparations which contain one or more of the abovementioned compounds together with conventional carriers, Auxiliaries and / or additives comprise, on the one hand, as a topical application in the form of, for example Creams, ointments, pastes, gels, solutions, sprays, liposomes and ⁇ anosomes, shake mixes, "pegylated” formulations, degradable (ie degradable under physiological conditions) depot matrices, hydrocolloid dressings, plasters, microsponges, prepolyomers and similar new carrier substrates, jet -Injection or other dermatological bases / vehicles including instillative application, and on the other hand as a systemic application for oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, intrathecal use in suitable formulations or in suitable galenics.
- the compounds of the general formulas AI to AI 4 in general and preferably the compounds AI.001 to AI 4.003 according to Tables 1 to 14 individually or in combination, or else pharmaceutical or cosmetic compositions which comprise one or more of the compounds mentioned Inhibition of the activity of alanyl aminopeptidases or analog enzymes used alone or in combination with inhibitors of dipeptidyl peptidase IV and inhibitors of analog enzymes.
- the compounds of the general formulas AI to A14 in general and preferably the compounds AI.001 to A14.003 according to Tables 1 to 14 individually or in combination, or else pharmaceutical or cosmetic compositions which comprise one or more of the mentioned compounds include, for topical influencing the activity of alanyl aminopeptidases or analogous enzymes used alone or in combination with inhibitors of Dipeptidylpeptidase TV and inhibitors of analogous enzymes.
- the compounds of the general formulas AI to AI 4 in general and preferably the compounds AI.001 to A14.003 according to Tables 1 to 14 are used individually or in combination, or else pharmaceutical or cosmetic compositions are used, which comprise one or more of the compounds mentioned, for the prophylaxis and therapy of diseases such as, for example, multiple sclerosis, Crohn's disease, ulcerative colitis, and other autoimmune diseases and inflammatory diseases, bronchial asthma and other allergic diseases, skin and mucous membrane diseases, for example psoriasis, Acne and dermatological diseases with hyperproliferation and altered differentiation states of fibroblasts, benign fibrosing and sclerosing skin diseases and malignant fibroblastic hyperproliferation states, acute neuronal diseases, such as ischemia-bed Severe cerebral damage after an ischemic or hemorrhagic stroke, skull / brain trauma, cardiac arrest, heart attack or as a result of cardiac surgery, chronic neuronal diseases, for example Alzheimer's disease, Pick's
- diseases such as, for
- the compounds of the general formulas AI to AI 4 are used in general and preferably the compounds AI.001 to A14.003 according to Tables 1 to 14 individually or in combination, or else the pharmaceutical or cosmetic compositions, which comprise one or more of the compounds mentioned, for the prophylaxis and therapy of the rejection of trans planted tissues and cells.
- the use of one or more of the above-mentioned compounds or a pharmaceutical composition containing one or more of the above-mentioned compounds in allogeneic kidney or stem cell transplants can be mentioned.
- the compounds of the general formulas AI to A14 are used in general and preferably the compounds AI.001 to A14.003 according to Tables 1 to 14 individually or in combination, or else the pharmaceutical or cosmetic compositions which comprise one or more of the compounds mentioned, for the prophylaxis and therapy of the rejection or inflammatory reactions on or by medical objects implanted in an organism (“medical devices”).
- the compounds of the general formulas AI to A14 are used in general and preferably the compounds AI.001 to A14.003 according to Tables 1 to 14 individually or in Combination, or the pharmaceutical Chen or cosmetic compositions, which comprise one or more of the compounds mentioned, in such a way that the compounds) or composition (s) in the form of a coating or wetting are applied to the article or articles or at least one of the compounds or compositions as a substance is mixed with the material of the object (s). In this case too, it is of course possible to administer at least one of the compounds or compositions locally or systemically, if appropriate in chronological order or in parallel.
- the compounds of the general formulas AI to A14 in general and the compounds A1.001 to A14 can be used in the same way as described above - and for the comparable purposes or for the prophylaxis and therapy of the diseases and conditions mentioned by way of example but not exhaustively.
- 003 according to Tables 1 to 14 in preferred embodiments, and the pharmaceutical and cosmetic compositions described above and containing the compounds mentioned, alone or in Combination of several of them can be used to manufacture medicines to treat the above diseases or conditions.
- These may include the compounds mentioned in the amounts mentioned above, if appropriate together with carriers, auxiliaries and / or additives known per se.
- the invention also relates to a method for inhibiting the activity of the alanyl aminopeptidases or analogous enzymes alone or in combination with inhibitors of the DPIV and analogous enzymes by the administration of at least one compound or pharmaceutical or cosmetic composition according to the detailed description above in one for the inhibition of the Enzyme activity required amount.
- the amounts of one of the compounds of the general formulas AI to AI 4 in general or of the compounds AI.001 to A14.003 according to Tables 1 to 14 are - as indicated above - in the range from 0.01 to 1000 mg of a compound per administration unit, preferably in the range of 0.1 to 100 mg per administration unit.
- the invention also relates to a method for topically influencing the activity of the alanyl ammopeptidases or analogous enzymes alone or in combination with inhibitors of the DPIV or analogous enzymes by administration of at least one compound or pharmaceutical or cosmetic composition according to the detailed description above in one for the influencing the amount of enzyme activity required.
- the amounts of the compound (s) are in the range given above.
- the invention also relates to a method for the prophylaxis and therapy of a large number of diseases, for example diseases with an excessive immune response (autoimmune diseases, allergies and transplant rejections), other chronic inflammatory diseases, neuronal diseases and cerebral damage, skin diseases (including acne and psoriasis), Tumor diseases and special viral infections (including SARS) and in particular the diseases mentioned in detail above, by administration of at least one compound or pharmaceutical or cosmetic composition according to the detailed description above in an amount required for the prophylaxis or therapy of the respective disease.
- diseases with an excessive immune response autoimmune diseases, allergies and transplant rejections
- other chronic inflammatory diseases include neuronal diseases and cerebral damage
- skin diseases including acne and psoriasis
- Tumor diseases and special viral infections including SARS
- the amounts of the compound (s) range from 0.01 to 1000 mg of a compound per administration unit, preferably in the range from 0.1 to 100 mg per administration unit.
- Tables 1 to 14 below summarize new inhibitors for which the applicants have shown that they are capable of inhibiting the enzymatic activity of alanyl aminopeptidases.
- the measured inhibition characteristics are given as IC-50 or ID-50 values (the latter marked with “*”) for both enzymes.
- the enzymatic activity was determined with the aid of the fluorogenic substrate product (Ala) 2 - rhodamine 110.
- the disease scores [vDl] are defined by different degrees of paralysis. Healthy animals have a disease score of 0. Actinonin was used as the alanyl aminopeptidase inhibitor and Lys [Z ( ⁇ O2)] pyrrolidide as the dipeptidylpeptidase IN inhibitor. Treatment was continued for 46 days after immunization. The results can be seen in FIG. 1. The curves clearly show a strongest and most lasting [vD2] therapeutic effect after combined inhibition of both peptidases.
- Inflammation predominantly affecting the colon was induced by ner administration of 3% sodium dextran sulfate in drinking water in 8-week-old female Balb / c mice. After 3 days, all animals show clear symptoms typical of the disease.
- the peptidase inhibitors and the phosphate-buffered saline as placebo were administered intraperitoneally from day 5 on for three consecutive days. The severity is determined using a recognized rating system.
- Sensitization to the bronchial-inducing antigen ovalbumin was carried out on female Balb / c mice by intraperitoneal administration of 10 ⁇ g ovalbumin each on days 0, 14 and 21. On days 27/28, the animals were boosted by inhalation with ovalbumin [vD3]. After intraperitoneal application of the peptidase inhibitors on days 28-35, an intranasal ovalbumin challenge was carried out on day 35 and the early allergic reaction via the lung function was checked. The mean expiratory flow EF50, the tidal volume, the respiratory rate and the minute volume as well as the number of eosinophilic granulocytes in the bronchoalveolar lavage were measured.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10348023A DE10348023A1 (en) | 2003-10-15 | 2003-10-15 | New alanyl aminopeptidase inhibitors for the functional manipulation of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
PCT/EP2004/011643 WO2005037257A2 (en) | 2003-10-15 | 2004-10-15 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1673075A2 true EP1673075A2 (en) | 2006-06-28 |
Family
ID=34441990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04790485A Withdrawn EP1673075A2 (en) | 2003-10-15 | 2004-10-15 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070037752A1 (en) |
EP (1) | EP1673075A2 (en) |
JP (1) | JP2007508349A (en) |
CN (1) | CN1897928A (en) |
AU (1) | AU2004281536B9 (en) |
CA (1) | CA2542723A1 (en) |
DE (1) | DE10348023A1 (en) |
WO (1) | WO2005037257A2 (en) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004085382A1 (en) * | 2003-03-27 | 2004-10-07 | Kirin Beer Kabushiki Kaisha | Compound inhibiting in vivo phosphorus transport and medicine containing the same |
JP2006521377A (en) | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | New IDO inhibitors and methods of use |
DE10348022A1 (en) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
US20060194810A1 (en) * | 2004-04-30 | 2006-08-31 | Bijan Almassian | Methods of treating ischemic related conditions |
JP2008517061A (en) * | 2004-10-20 | 2008-05-22 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | Compounds as antitumor agents and their use |
US7994221B2 (en) | 2004-12-06 | 2011-08-09 | Siga Technologies, Inc. | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
US8410149B2 (en) | 2004-12-06 | 2013-04-02 | Siga Technologies Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
WO2006062898A2 (en) | 2004-12-06 | 2006-06-15 | Siga Technologies, Inc. | Compounds and methods for treating hemorrhagic fever viruses |
US7544838B2 (en) * | 2005-01-21 | 2009-06-09 | City Of Hope | Ligands for estrogen related receptors and methods for synthesis of said ligands |
ITMI20050261A1 (en) * | 2005-02-21 | 2006-08-22 | Carlo Ghisalberti | STRUCTURAL ANALOGS OF AVENATRAMIDS THEIR USE IN USEFUL COMPOSITIONS IN THE TREATMENT OF DERMATOLOGICAL DISORDERS |
US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
WO2006094248A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Aryl-substituted cyclic sirtuin modulators |
EA026785B1 (en) | 2005-05-10 | 2017-05-31 | Инсайт Холдингс Корпорейшн | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
WO2006132583A1 (en) * | 2005-06-07 | 2006-12-14 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection |
WO2006138266A2 (en) * | 2005-06-14 | 2006-12-28 | Schering Corporation | The preparation and use of compounds as aspartyl protease inhibitors |
US20070135499A1 (en) * | 2005-07-11 | 2007-06-14 | Aerie Pharmaceuticals, Inc. | Hydrazide compounds |
EP1910297B1 (en) | 2005-07-11 | 2016-05-25 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
EP2338878A3 (en) * | 2005-12-15 | 2011-11-16 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
ES2540561T3 (en) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hydroxyamidinoheterocycles as indolamine 2,3-dioxygenase modulators |
US8791110B2 (en) | 2006-02-01 | 2014-07-29 | Siga Technologies, Inc. | Anti-arenaviral compounds |
US8106058B2 (en) | 2006-02-01 | 2012-01-31 | Siga Technologies, Inc. | Anti-arenaviral compounds |
US7977365B2 (en) | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
EP1988884A4 (en) | 2006-03-02 | 2009-09-30 | Siga Technologies Inc | Antiviral drugs for treatment of arenavirus infection |
US8871746B2 (en) | 2006-03-02 | 2014-10-28 | Kineta Four, LLC | Antiviral drugs for treatment of arenavirus infection |
EP1988776B1 (en) | 2006-03-02 | 2012-08-08 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
DE102006028862A1 (en) * | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-amino-imidazo [1,2-a] pyridine |
US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
PT2155747E (en) * | 2007-05-10 | 2012-12-19 | Ge Healthcare Ltd | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
EP2003125A1 (en) * | 2007-06-14 | 2008-12-17 | Total Petrochemicals Research Feluy | New tridentate ligand compounds with imino furan units, method for manufacturing said compounds, and their use in the preparation of catalysts for the homopolymerisation and copolymerisation of ethylene and alpha-olefins |
WO2009009768A2 (en) * | 2007-07-12 | 2009-01-15 | Acumen Pharmaceuticals, Inc. | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS |
US8962677B2 (en) * | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
US9006283B2 (en) * | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
US8637560B2 (en) * | 2007-07-18 | 2014-01-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment |
CN101990534A (en) * | 2007-11-01 | 2011-03-23 | Uab研究基金会 | Treating and preventing viral infections |
US9217024B2 (en) | 2007-12-18 | 2015-12-22 | Acumen Pharmaceuticals, Inc. | ADDL receptor polypeptides, polynucleotides and host cells for recombinant production |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
FR2926463B1 (en) * | 2008-01-22 | 2010-08-13 | Centre Nat Rech Scient | USE OF AMINOPEPTIDASE INHIBITORS OR AZAINDOLE COMPOUNDS FOR PREVENTING OR TREATING CANCER METASTASES OF EPITHELIAL ORIGIN |
TWI490214B (en) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | Benzene or thiophene derivative and use thereof as vap-1 inhibitor |
CN104042611B (en) | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 1 of inhibitor as indoleamine 2,3-dioxygenase, 2,5- oxadiazoles |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US20120122889A1 (en) * | 2008-12-23 | 2012-05-17 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
WO2010072807A2 (en) * | 2008-12-23 | 2010-07-01 | Fondation Jerome Lejeune | Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide |
WO2010080183A1 (en) | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
US8889674B2 (en) | 2009-03-05 | 2014-11-18 | Shionogi & Co., Ltd. | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism |
ES2665277T3 (en) * | 2009-03-13 | 2018-04-25 | Katholieke Universiteit Leuven K.U. Leuven R&D | Purine analogues and their use as immunosuppressive agents |
US20100248365A1 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Ganglioside biosynthesis modulators |
WO2010126002A1 (en) * | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | Pharmaceutical product containing heterocyclic sulfonamide compound |
EP3828172A1 (en) | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
WO2011006158A2 (en) * | 2009-07-10 | 2011-01-13 | University Of Maryland, Baltimore | Targeting nad biosynthesis in bacterial pathogens |
US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
US8242282B2 (en) | 2010-05-18 | 2012-08-14 | Taipei Medical University | Histone deacetylase inhibitors |
TWI457323B (en) * | 2010-05-19 | 2014-10-21 | Univ Taipei Medical | Histone deacetylase inhibitors |
CN102267923B (en) * | 2010-06-04 | 2015-07-15 | 台北医学大学 | Histone deacetylase inhibitors |
US9255088B2 (en) | 2010-08-11 | 2016-02-09 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
CN102631664B (en) * | 2011-01-28 | 2014-10-01 | 上海来益生物药物研究开发中心有限责任公司 | Application of 3-amino-2-hydroxy-4-phenyl-valyl-isoleucine |
US9598395B2 (en) | 2012-03-23 | 2017-03-21 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
NZ704666A (en) * | 2012-08-23 | 2018-05-25 | Alios Biopharma Inc | Compounds for the treatment of paramoxyvirus viral infections |
EP3336080A1 (en) | 2013-02-26 | 2018-06-20 | Microbial Chemistry Research Foundation | Novel compound, production method therefor, and use of said compound |
EP3811943B1 (en) | 2013-03-15 | 2023-02-22 | Aerie Pharmaceuticals, Inc. | Compound for use in the treatment of ocular disorders |
EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
CN105246483A (en) | 2013-03-15 | 2016-01-13 | 癌症研究技术有限责任公司 | Methods and compositions for gamma-glutamyl cycle modulation |
ES2526580B1 (en) * | 2013-07-08 | 2015-10-23 | Consejo Superior De Investigaciones Científicas (Csic) | Use of a compound of formula (I) as a bactericide against Streptococcus |
UA123854C2 (en) | 2013-08-21 | 2021-06-16 | Аліос Біофарма, Інк. | Antiviral compounds |
TW202309014A (en) | 2013-11-08 | 2023-03-01 | 美商英塞特控股公司 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
GB201321749D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015119249A1 (en) * | 2014-02-07 | 2015-08-13 | 国立大学法人東京医科歯科大学 | Myogenesis accelerator, amyotrophy suppressor, medicinal composition, and taz activator |
JP2017518312A (en) * | 2014-06-05 | 2017-07-06 | ユニバーシティ・オブ・カンザス | Malmelin analogs and methods of use in cancer treatment |
JP2018502158A (en) * | 2015-01-12 | 2018-01-25 | レビバ ファーマシューティカルズ,インコーポレイティド | Treatment of psychosis associated with Parkinson's disease |
JP2018502157A (en) * | 2015-01-12 | 2018-01-25 | レビバ ファーマシューティカルズ,インコーポレイティド | Treatment of Alzheimer's disease |
MA41614A (en) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | ANTIVIRAL COMPOUNDS |
EP3108883A1 (en) * | 2015-06-22 | 2016-12-28 | Fundació Institut de Recerca Biomèdica de Bellvitge | Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway |
JP6832946B2 (en) | 2015-11-17 | 2021-02-24 | アエリエ ファーマシューティカルズ インコーポレイテッド | How to prepare kinase inhibitors and their intermediates |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
DK3388420T3 (en) * | 2015-12-07 | 2022-09-26 | Hinova Pharmaceuticals Inc | Quinoline compounds, method of preparation thereof and use thereof as urate transporter inhibiting drug |
CN109641884B (en) | 2016-08-18 | 2024-01-02 | 维达克制药有限公司 | Piperazine derivatives, pharmaceutical compositions thereof, and methods of use thereof |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
CN106496108B (en) * | 2016-11-01 | 2019-05-31 | 上海应用技术大学 | Amides compound with anti-tumor activity and its application |
MX2019011784A (en) | 2017-03-31 | 2019-11-18 | Aerie Pharmaceuticals Inc | Aryl cyclopropyl-amino-isoquinolinyl amide compounds. |
US10471045B2 (en) * | 2017-07-21 | 2019-11-12 | The University Of Hong Kong | Compounds and methods for the treatment of microbial infections |
US11474098B2 (en) | 2017-12-22 | 2022-10-18 | The Trustees Of Columbia University In The City Of New York | Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same |
EP3849555A4 (en) | 2018-09-14 | 2022-05-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
EP3858342A1 (en) * | 2018-09-27 | 2021-08-04 | Consejo Superior de Investigaciones Científicas (CSIC) | Acylhydrazones for the treatment of neurological diseases |
CN111249283A (en) * | 2018-11-30 | 2020-06-09 | 四川大学 | Pyrimidine derivatives having anticancer effect |
WO2020142729A1 (en) * | 2019-01-04 | 2020-07-09 | BellBrook Labs | Inhibitors of cgas activity as therapeutic agents |
EP3946301A4 (en) * | 2019-04-02 | 2023-08-09 | The University of Chicago | Remodilins for airway remodeling and organ fibrosis |
CN113750088A (en) * | 2021-09-16 | 2021-12-07 | 中国人民解放军海军特色医学中心 | Application of heterocyclic compound in preparation of medicine for treating ulcerative colitis |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639794A (en) * | 1995-06-07 | 1997-06-17 | Proguard, Inc. | Use of saponin in methods and compositions for pathogen control |
DE19823831A1 (en) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | New pharmaceutical use of isoleucyl thiazolidide and its salts |
DE10025464A1 (en) * | 2000-05-23 | 2001-12-06 | Inst Medizintechnologie Magdeb | Combined use of enzyme inhibitors for the therapy of autoimmune diseases, in transplants and tumor diseases, as well as combinations of pharmaceutical preparations comprising enzyme inhibitors |
CA2436724C (en) * | 2001-01-02 | 2010-03-16 | Siegfried Ansorge | Use of inhibitors of dipeptidyl peptidase iv (dp iv) in combination with inhibitors of alanyl-aminopeptidase (apn) |
DE10100053A1 (en) * | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Use of enzyme inhibitors of dipeptidyl peptidase IV and aminopeptidase N and pharmaceutical preparations therefrom for the prevention and / or therapy of ischemia-related acute and chronic neurodegenerative processes and diseases |
ATE353900T1 (en) * | 2001-02-24 | 2007-03-15 | Boehringer Ingelheim Pharma | XANTHINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
GB0125446D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
EP2316470A3 (en) * | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
DE10211555A1 (en) * | 2002-03-15 | 2003-10-02 | Imtm Inst Fuer Medizintechnolo | Use of the inhibitors of enzymes with activities of the aminopeptidase N and / or the dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of dermatological diseases with sebocytic hyperproliferation and changed differentiation states |
DE10230381A1 (en) * | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them |
US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10337074A1 (en) * | 2003-08-12 | 2005-03-17 | Keyneurotek Ag | Use of the inhibitors of enzymes with activities of aminopeptidase N and / or dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of chronic neurodegenerative diseases |
-
2003
- 2003-10-15 DE DE10348023A patent/DE10348023A1/en not_active Ceased
-
2004
- 2004-10-15 JP JP2006534706A patent/JP2007508349A/en active Pending
- 2004-10-15 AU AU2004281536A patent/AU2004281536B9/en not_active Ceased
- 2004-10-15 US US10/575,882 patent/US20070037752A1/en not_active Abandoned
- 2004-10-15 CN CNA2004800364568A patent/CN1897928A/en active Pending
- 2004-10-15 CA CA002542723A patent/CA2542723A1/en not_active Abandoned
- 2004-10-15 WO PCT/EP2004/011643 patent/WO2005037257A2/en active Application Filing
- 2004-10-15 EP EP04790485A patent/EP1673075A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2005037257A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2542723A1 (en) | 2005-04-28 |
US20070037752A1 (en) | 2007-02-15 |
JP2007508349A (en) | 2007-04-05 |
CN1897928A (en) | 2007-01-17 |
AU2004281536B2 (en) | 2009-07-09 |
WO2005037257A2 (en) | 2005-04-28 |
WO2005037257A3 (en) | 2006-09-14 |
DE10348023A1 (en) | 2005-05-19 |
AU2004281536A1 (en) | 2005-04-28 |
AU2004281536B9 (en) | 2009-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005037257A2 (en) | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | |
EP1673082A2 (en) | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases | |
EP1675594A2 (en) | Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | |
DE60128651T2 (en) | THIAZOLE-IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENT OF PROTEIN-ASSOCIATED DISEASES | |
EP1948627B1 (en) | Novel dual peptidase inhibitors as prodrugs for the therapy of inflammatory and other disorders | |
EP2046732B1 (en) | Improvement of the bioavailability of active substances having an amidine function in medicaments | |
DE69632854T2 (en) | Protective agent for organs and tissues | |
EP2178527A1 (en) | Method for activating regulatory t-cells | |
DE3619426A1 (en) | AGENT FOR INCREASING RESISTANCE TO COLD DISEASES IN PATIENTS WITH RESTRICTED LUNG FUNCTION | |
EP1720549A1 (en) | Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency | |
EP0951907B1 (en) | Use of moxonidine as a thermogenesis stimulating agent | |
WO2013014059A1 (en) | Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs | |
EP0845264A1 (en) | Partial or full extract of non fermentated Camellia sinensis L. | |
EP2001555A1 (en) | Use of strobilurins for treating malfunctions of the iron metabolism | |
DE2028880A1 (en) | N-phenyl carbamoyl derivs of 3-beta-phenyl isopropyl-synononimines - - as psycho and cns | |
WO2004024149A1 (en) | Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases | |
DE102008031036A1 (en) | Use of 4-aminothiazolpyrimidine derivatives for the treatment of associated organ transplants | |
EP1528922B1 (en) | Use of treosulfan and derivatives thereof for treating multiple sclerosis | |
DE10261808A1 (en) | Use of L-DOPA, its derivatives and medicaments containing these compounds for the prophylaxis of psychotic diseases | |
DE2651947A1 (en) | Compsns. contg. glucaric acid or its derivs. - useful as antibacterial and antifungal medicaments, food preservatives, microbicides and disinfectants | |
DE4301739A1 (en) | Treatment of primary tumours and viral diseases | |
EP1087768A1 (en) | Use of 1-(aminoalkyl)-3-quinoxaline-2-one derivatives for the preparation of compounds having an antioxidant action | |
EP1404322A2 (en) | 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof | |
DE2915158A1 (en) | 2-HYDROXY BENZOATE OF 1-BENZYL-1H-INDAZOLE-3-YL-3- (DIMETHYLAMINE) -PROPYLAETHER, PROCESS FOR THE PREPARATION THEREOF AND MEDICINAL PRODUCT | |
DE2131676A1 (en) | 3,4,5-Trialkoxybenzoylalkanecarboxylic acids and their salts and medicinal preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060331 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KEYNEUROTEK PHARMACEUTICALS AG Owner name: IMTM GMBH |
|
17Q | First examination report despatched |
Effective date: 20080819 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100921 |